During the last decade, pharma marketers have seen biopharma companies shift their investment from large therapeutic areas to specialty therapeutics. This made sense, because of the large unmet needs in specialty areas in contrast to saturated- and generics-dominated therapy areas. In specialty areas, many companies rightfully saw great opportunities to develop therapies with compelling claims.…
The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin’s latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
The latest IMS Institute for Healthcare Informatics assessment of 2013’s prescription drug use shows that 2.3% of prescriptions account for 30% of a patient’s out-of-pocket prescription costs.
AI Deciphered: Discovering the Potential for Marketers and Communicators